Welcome to the Association of Cannabinoid Specialists' Doc Talk Blog, where you'll find the most up-to-date science, news, advocacy, and updates from cannabinoid specialists and other experts in the fields of cannabinoid medicine, policy, industry, education, and more.
We will never be able to prove whether or not cannabis causes psychosis. The research methods that could prove the point are simply unethical to employ.
Written by Amcs Admin
September 29, 2026
Over the past decade, cannabis-based therapeutics have rapidly transitioned from controversial alternative remedies to serious subjects of scientific and clinical investigation. As legalization expands across the United States and globally, patients are increasingly comparing conventional FDA-approved medications with cannabis products for conditions such as chronic pain, epilepsy, anxiety, neurological disorders, and cancer-related symptoms.
As cannabis legalization continues to expand across the United States and globally, the cannabis industry has experienced rapid growth in the production and commercialization of edibles, oils, vape cartridges, tinctures, concentrates, and infused beverages. While much scientific attention has focused on the therapeutic potential of cannabis, an equally important public health concern has emerged surrounding the packaging safety of cannabis products.
August is Women's Month in South Africa, a time to celebrate the resilience, strength, and health of women while acknowledging the unique healthcare challenges they face throughout their lives.
Every August, something magical happens in American politics: Congress packs up for its traditional August recess, and a good chunk of state legislatures wind down their sessions around the same time.
GLP-1 receptor agonists and cannabinoids both slow gastrointestinal motility, so concurrent use can meaningfully increase the risk of delayed gastric emptying, gastroparesis-like symptoms, and nausea–vomiting syndromes in susceptible patients. Clinicians should therefore screen for cannabis use when starting GLP‑1 agents and counsel patients about overlapping GI toxicities and red-flag symptoms.[1][2][3][4]
Written by Jordan Tishler, MD
July 21, 2026
Many states require doctors, nurses, and pharmacists to take special training courses before they can recommend medical cannabis to patients. However, the quality of these required courses varies wildly. Some courses focus on outdated laws or retail business tips rather than real clinical practice and evidence.
Written by Amcs Admin
July 07, 2026
North Carolina should not mistake retail access for medical care.North Carolina must not bypass establishing a medical cannabis program in favor of a retail cannabis sales only program. A comprehensive medical system is needed and intended to serve the unmet needs of sick North Carolinians including counsel and oversight from medical professionals.
Written by Jordan Tishler, MD
June 26, 2026
Clinicians are seeing more patients who use cannabis. Some patients use it for medical purposes like insomnia, chronic pain, or anxiety. Others use it purely for enjoyment.
Nonetheless, we’re seeing that as use increases, so does a troubling diagnostic reflex: when a patient reports cannabis use along with nonspecific gastrointestinal symptoms, cannabis hyperemesis syndrome (CHS) too often becomes the default conclusion.
Written by Jordan Tishler, MD
June 16, 2026
Cannabidiol (CBD) is a non-intoxicating component of the cannabis plant. Scientific investigations over the past decade have clarified CBD’s potential as an anti-seizure medication, distinguishing its mechanism from both tetrahydrocannabinol (THC) and traditional antiepileptic drugs¹.
Written by Amcs Admin
June 02, 2026
Recreational use of alcohol and cannabis each carries significant risks, but the pattern, severity, and societal impact of these risks differ in important ways.
Written by Jordan Tishler, MD
May 19, 2026
What causes period pain, and what role does cannabinoid medicine play in alleviating symptoms?
With the federal repositioning of FDA-approved cannabinoid products and state-licensed medical cannabis from Schedule I to a Schedule III drug, federal regulators have recognized the medical value of cannabinoid medicine.
Written by Amcs Admin
April 28, 2026
Migraines and chronic headaches are more than just episodes of pain, they are complex neurological disorders that can significantly disrupt quality of life, productivity, and mental health.
Cannabis Is Here. The Public Health Work Is Just Beginning.Cannabis did not quietly arrive. It moved from the margins into everyday life with speed and scale. It now touches healthcare visits, workplace safety, insurance claims, disability evaluations, and conversations about fairness and enforcement. Whether someone supports legalization is no longer the defining issue. Cannabis is here. The real question is whether we are managing its impact with the same seriousness we apply to other widespread health exposures.
Medical cannabis provides clinically meaningful benefit for eligible patients when used under appropriate clinical supervision. Psychosis risk is real but concentrated in specific high-risk groups and use patterns. Any federal or state policy should strengthen safeguards within medical programs rather than restrict legitimate therapeutic access.
Written by Jordan Tishler, MD
April 05, 2026
Due to recent debate about hemp product regulation, there has been renewed interest in products labelled as “full spectrum” vs. “broad spectrum”. In this article, we will define these terms and explore their medical safety and utility.
Written by Jordan Tishler, MD
March 29, 2026
Cannabis-infused products are increasingly incorporating a diverse range of additional ingredients such as botanicals (e.g., corydalis), hormones (e.g., melatonin), minor cannabinoids, mushrooms, and even essential oils in pursuit of new branding angles and supposed therapeutic effects.
Written by Jordan Tishler, MD
March 24, 2026
March is Colorectal Cancer Awareness Month — an opportunity to highlight both progress and concern in colorectal cancer (CRC) prevention and management.
Written by Adam Abodeely
March 10, 2026
Current scientific evidence on the use of THC and CBD for Attention-Deficit/Hyperactivity Disorder (ADHD) remains limited and inconclusive, with potential for both benefit and harm. The Association of Cannabinoid Specialists recommends that clinicians consider available data and exercise caution, prioritizing established treatments and monitoring for cannabis use disorder when encountering patients with ADHD who use cannabinoids.
Written by Jordan Tishler, MD
February 24, 2026
The gut is home to a complex communication network that integrates neural, immune, and microbial inputs to maintain gastrointestinal health.
Love, sex, and cannabis make an appealing Valentine’s trio—but, like any good ménage à trois, they work best with clear communication, low drama, and correct dosing.
Written by Jordan Tishler, MD
February 08, 2026
Medical cannabis use from an Islamic perspective is a nuanced subject balancing religious principles, the prohibition of intoxication, and the therapeutic benefits of cannabis.
Written by Jordan Tishler, MD
January 27, 2026
Spain’s inclusion of standardized magistral (compounded) cannabinoid preparations in the National Formulary is a meaningful regulatory milestone that brings much‑needed national consistency, quality standards, and traceability to prescribed cannabis medicines.[1][2][3]
Written by Jordan Tishler, MD
January 23, 2026
Cannabis has a long-standing role in medicine and recently the United States Department of Health and Human Service (HHS) has declared it meets the standard of Commonly Accepted Medical Use (CAMU). Modern research has revealed its effectiveness and safety for multiple conditions. The United States Food and Drug Administration (FDA) has approved cannabinoid-based drugs for many years, and evidence suggests that current non-pharmaceutical cannabis products may offer even greater efficacy. Despite this, a majority of physicians are not fully aware of the therapeutic possibilities cannabinoids provide and often feel hesitant to prescribe them, even when patients could benefit.
Written by Jordan Tishler, MD
January 13, 2026
Cannabis is often touted as being a “cure-all” or panacea for a wide range of illnesses from chronic pain to anxiety to cancer to insomnia and others. Not only is this thinking medically invalid, it undermines the legitimate use of cannabinoid medications.
Written by Amcs Admin
December 30, 2025
On December 18, 2025 the United States government definitively declared “Cannabis IS Medicine”. Association of Cannabinoid Specialists (ACS) has been advocating that position since our physician-founder established our non-profit.
Written by Jordan Tishler, MD
December 19, 2025
The rise of cannabis-based medicine across Africa is reshaping how nations think about health, policy, and economic opportunity. Southern Africa presents a fascinating spectrum, from Zimbabwe’s export-driven approach to South Africa’s cautiously progressive model and Mauritius’s newly regulated framework.
Written by Sangeeta Nathoo
December 16, 2025
Disclaimer: This article was written in large part with the assistance of AI. While the basic tenets are familiar to me, as a fairly secular Jew, I claim no deep insight into the nuances of Jewish law.
Medical cannabis use within the Jewish perspective is approached thoughtfully through halakhic (Jewish law) and ethical frameworks that emphasize the sanctity of life, health, and moral living.
Written by Jordan Tishler, MD
December 02, 2025
A large number of cannabis and hemp industry advocacy groups as well as cannabis clinician groups have been emailing last week to “save hemp” in light of the federal budget that would re-criminalize “intoxicating hemp” products. At ACS we disagree with the positions both factions have taken.
Written by Jordan Tishler, MD
November 19, 2025